Drug Trial Radar · NCT07893106
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Oct 13, 2026
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Ascletis Pharma (China) Co., LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, double-blind, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of ASC36 Tablets for Oral Use in Adult Participants with Obesity or Overweight
Conditions
- Chronic Weight Management
Interventions
ASC36 tablets, for oral useDrug
ASC36 tablets are an investigational formulation of ASC36 administered orally
ASC36 placebo tabletsDrug
ASC36 placebo tablets are a plaecbo formulation matching ASC36 tablets, administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: From baseline to the end of treatment (up to 10 weeks or Day 70)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ascletis Clinical Site
South Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.